Denton Pharma dba Northwind Pharmaceuticals recalls all unexpired lots of its ranitidine tablets and ceases distribution

Denton Pharma, dba Northwind Pharmaceuticals, issued a voluntary recall of all unexpired lots of ranitidine tablets, 150 mg and 300 mg, due to the possible presence of N-nitrosodimethylamine (NDMA).

Denton Pharma, dba Northwind Pharmaceuticals, issued a voluntary recall of all unexpired lots of ranitidine tablets, 150 mg and 300 mg, due to the possible presence of N-nitrosodimethylamine (NDMA). The recall follows the manufacturer's recall of all unexpired lots of ranitidine tablets, 150 mg and 300 mg, that were repackaged by Denton Pharma, dba Northwind Pharmaceuticals. Thus far, Northwind has received no reports of adverse events that were confirmed to be directly related to the recall. Northwind noted that as an additional precautionary measure, it has halted distribution of its ranitidine products in the United States while it continues its efforts to test and investigate in cooperation with FDA.